web analytics
16.5 C
Sunday, May 22, 2022

Why Cannabis Science Inc (OTCMKTS:CBIS) Outstands among Marijuana Stocks?

Cannabis Science Inc (OTCMKTS:CBIS) is one pot stock that has been here from the beginning making several spectacular runs over the past several years. CBIS has been at the forefront of this incredible phenomenon trading massive volume and rising to incredible highs CBIS continues to be one of the top traded stocks on the entire bb’s.

The general consensus seems to be that cannabinoids (one of the major ingredients of Cannabis besides the THC) are a miracle cure for neurological disorders and seizures as well as the much needed synergistic maintenance therapy to improve the lives and treatment of cancers and HIV

This euphoria has driven pot stocks sky high; just over the past few years CBIS has seen no less than two runs that saw absolutely spectacular gains with the stock easily running over 1000% both times. As the market valuations of these Companies have exploded some suggest that they are justified as the industry is expected to pull in tens of billions of dollars; even a small piece of the massive pie would validate these high market valuations.

To Find out the inside Scoop on CBIS Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate.

The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment of illnesses caused by infections as well as for age-related disease. Our initial focus is on skin cancers, neurological conditions, and licensing of Company knowhow to partners worldwide.

Historically CBIS operated business in a variety of industries under multiple aliases, “Patriot Holdings” in 1996, “National Healthcare Technology, Inc.” in 1999, “Special Stone Surfaces” in 2005, “Brighton Oil & Gas” in 2007, and “Gulf Onshore, Inc.” in 2008. These scattered and unsuccessful business ventures ranged from biotechnological R&D, oil and gas exploration, mineral leasing and significant M&A activities.

Since May 2009 after the Company changed their name to Cannabis Science Inc the Company has been focused on among many other projects in the Cannabis sector:

First, the CS-S/BCC-1 drug program was launched in 2011 due to the “apparent success in 4 skin cancer patients who have self-administered cannabinoid based extracts topically to their skin cancers. These patients have experienced shrinking and apparent eradication of their skin cancer lesions.”

Second, the drug CS-TATI-1 aims to target patients with drug-resistant HIV strains. The earliest article I could find relating to the launch of this program was in June 5, 2012, where the company loosely described a mission to “explore the commercial development of Phytocannabinoid-based therapeutics for drug resistant HIV infection.”

On September 29 CBIS announced they have signed a Drug Development and Laboratory Services Agreement with ImmunoClin Corporation (IMCL); Collaboration to Advance Clinical Studies and Formulations of the Company’s Proprietary Cannabinoid Based Products

Cannabis Science anticipates that ImmunoClin will commence cannabinoid-based drug formulation at its laboratories within the coming weeks, including advanced development of Cannabis Science’s proprietary neurological drug, tentatively designated as “CS-Neuro-1”. This contract complements the Company’s agricultural and research programs in Spain, Italy and other European countries.

Conclusion: CBIS continues to be THE POT STOCK to watch when the industry heats up; earlier this year the stock ran from $0.03 to $0.30 before collapsing after the CANN halt with the rest of the sector. As we came into November it heated up again and exploded off its $0.5 base to highs of $0.10 per share.

Now that Marijuana is legalized in Alaska, Oregon and Washington DC (already legal in Colorado and Washington) the entire industry is sure to continue to get massive publicity and which will trickle down to penny stocks such as CBIS.

Currently trading at a $55 million market valuation CBIS is trading near the bottom of its range and just over $0.05 support level and pivot point from the past. If pot stocks heat up CBIS can be counted on to explode to the upside and deserves to be at the top of investors watch lists here.

We have a Monster Pick Coming. Subscribe Right Now!

Disclosure: we hold no position in CBIS either long or short and we have not been compensated for this article.

More articles


Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.